Patterns and Predictors of Statin Therapy After Ischemic Stroke and TIA: Insights from the LIPYDS Multicenter Study

Background: Patients with ischemic stroke (IS) or TIA face an elevated cardiovascular risk, warranting intensive lipid-lowering therapy. Despite recommendations, adherence to guidelines is suboptimal, leading to frequent undertreatment. This study aims to evaluate the statin use after IS and TIA.

Methods: LIPYDS is a multicenter, observational, retrospective study including ≥ 18-year-old patients discharged after IS/TIA from 19 Italian centers in 2021. Multivariable logistic regression analysis was used to determine (1) the association between statin prescription (Any-statin versus No-statin), type (High-Intensity-statin versus Other-statin [Moderate/Low-Intensity]) with stroke etiology (TOAST), (2) clinical variables independently associated with statin prescription in the entire cohort and within TOAST categories.

Results: We included 3,740 patients (median age 75 [IQR 64-82]; median LDL-C 104 [IQR 79-131]). At discharge, 1,971 (52.7%) received a High-intensity-statin, 800 (21.4%) Other-statin, 969 (25.9%) No-statin therapy. Among patients not on statin therapy before the event (N = 2686 [71.8%]), 50.1% initiated High-intensity-statin (78.2% of those with Large-Artery-Atherosclerosis, 60.8% Small-Vessel-Disease, 34.7% Cardioembolic, 47.4% Undetermined etiology); in 33% the decision to abstain from initiating statin therapy persisted. Large-Artery-Atherosclerosis showed the strongest association with Any-statin (aOR 3.07 [95%CI 2.39-3.95], p < 0.001) and High-intensity-statin (aOR 4.51 [95%CI 3.39-6.00], p < 0.001), while Cardioembolic stroke showed an inverse association (respectively, aOR 0.36 [95%CI 0.31-0.43], p < 0.001 and aOR 0.52 [95%CI 0.44-0.62], p < 0.001). Stepwise regression highlighted LDL-C and previous statin therapy as consistent predictors of statin at discharge. Older patients and women were less likely to be on a high-intensity formulation.

Conclusion: Statins, especially at high-intensity, are under-prescribed after IS and TIA, with older patients, women and those with non-atherosclerotic strokes being the most affected.

References

Chou R, Cantor A, Dana T, Wagner J, Ahmed A, Fu R . Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022; 328(8):754-771. DOI: 10.1001/jama.2022.12138. View

Amarenco P, Labreuche J . Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009; 8(5):453-63. DOI: 10.1016/S1474-4422(09)70058-4. View

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

Lee M, Cheng C, Wu Y, Lee J, Hsu C, Ovbiagele B . Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA Neurol. 2022; 79(4):349-358. PMC: 8861901. DOI: 10.1001/jamaneurol.2021.5578. View

Nelson A, Haynes K, Shambhu S, Eapen Z, Cziraky M, Nanna M . High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. J Am Coll Cardiol. 2022; 79(18):1802-1813. PMC: 9344279. DOI: 10.1016/j.jacc.2022.02.048. View

Ray K, Molemans B, Schoonen W, Giovas P, Bray S, Kiru G . EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021; 28(11):1279-1289. DOI: 10.1093/eurjpc/zwaa047. View

Yao X, Shah N, Gersh B, Lopez-Jimenez F, Noseworthy P . Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. JAMA Netw Open. 2020; 3(11):e2025505. PMC: 7679951. DOI: 10.1001/jamanetworkopen.2020.25505. View

Canavero I, Cavallini A, Perrone P, Magoni M, Sacchi L, Quaglini S . Clinical factors associated with statins prescription in acute ischemic stroke patients: findings from the Lombardia Stroke Registry. BMC Neurol. 2014; 14:53. PMC: 3994484. DOI: 10.1186/1471-2377-14-53. View

Yang Z, Edwards D, Massou E, Saunders C, Brayne C, Mant J . Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study. Clin Epidemiol. 2019; 11:495-508. PMC: 6607979. DOI: 10.2147/CLEP.S201983. View

10.

Adams Jr H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35-41. DOI: 10.1161/01.str.24.1.35. View

11.

Hackam D, Hegele R . Cholesterol Lowering and Prevention of Stroke. Stroke. 2019; 50(2):537-541. DOI: 10.1161/STROKEAHA.118.023167. View

12.

Yaghi S, Elkind M . Lipids and Cerebrovascular Disease: Research and Practice. Stroke. 2015; 46(11):3322-8. PMC: 4624572. DOI: 10.1161/STROKEAHA.115.011164. View

13.

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

14.

Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein L, Hennerici M, Rudolph A . High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355(6):549-59. DOI: 10.1056/NEJMoa061894. View

15.

Amarenco P, Benavente O, Goldstein L, Callahan 3rd A, Sillesen H, Hennerici M . Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009; 40(4):1405-9. DOI: 10.1161/STROKEAHA.108.534107. View

16.

Amarenco P, Kim J, Labreuche J, Charles H, Abtan J, Bejot Y . A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2019; 382(1):9. DOI: 10.1056/NEJMoa1910355. View

17.

Bach F, Skajaa N, Esen B, Fuglsang C, Horvath-Puho E, Sorensen H . High-intensity versus moderate-intensity statin treatment for patients with ischemic stroke: Nationwide cohort study. Eur Stroke J. 2023; 8(4):1041-1052. PMC: 10683733. DOI: 10.1177/23969873231193288. View

18.

Dearborn-Tomazos J, Hu X, Bravata D, Phadke M, Baye F, Myers L . Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke. 2021; 52(8):2521-2529. DOI: 10.1161/STROKEAHA.120.030089. View

19.

Amarenco P, Kim J, Labreuche J, Charles H, Giroud M, Lee B . Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial. Stroke. 2022; 53(11):3260-3267. DOI: 10.1161/STROKEAHA.122.039728. View

20.

Aivo J, Ruuskanen J, Tornio A, Rautava P, Kyto V . Lack of Statin Therapy and Outcomes After Ischemic Stroke: A Population-Based Study. Stroke. 2023; 54(3):781-790. PMC: 10561684. DOI: 10.1161/STROKEAHA.122.040536. View